
What Effective CDMO Oversight Looks Like
Effective CDMO oversight is more than audit frequency. How sponsors keep product knowledge, quality agreements and decisions under control.
Practical perspectives on inspection readiness, CDMO oversight, Annex 1 and quality leadership. Written by GMP Bridge’s senior consultants, drawing on their work with sponsors, CDMOs and manufacturing sites.
From signal to decision. A monthly brief for Quality, Operations and CMC leaders responsible for consequential GMP decisions.

Effective CDMO oversight is more than audit frequency. How sponsors keep product knowledge, quality agreements and decisions under control.

FDA Form 483 response guide: the 15-day window, systemic risk and credible, defensible commitments.

Annex 1 gaps still open after your gap assessment? Why they stay and how to close them for good.

FDA CMC flexibilities for cell and gene therapy: what the guidance allows and what sponsors must still prove.

What quality leaders get wrong about batch release time reduction in biopharma — and how to fix it. Practical insights from GMP Bridge.

How AI is transforming quality management in biopharma. Practical insights on AI-driven GMP compliance, deviation management & batch release.

Biopharma due diligence: how GMP audits shape smarter M&A decisions, what they cover, and the recurring pitfalls.

FDA readiness for European biopharma and CDMO sites: what it takes to meet FDA expectations and avoid a failed PAI.

How EU cell and gene therapy sites prepare for a first FDA PAI inspection and PLI, and where it differs from EMA.

5 steps to succeed in your first 100 days as a quality leader in biopharma. Practical guidance on priorities, quick wins & team alignment.

How to simplify your QMS in biologics & ATMP. Reduce GMP bottlenecks, cut complexity & scale with confidence. Insights by GMP Bridge.

Why QA needs a seat at the leadership table in biopharma. Insights on quality culture, strategic QA roles & business impact from GMP Bridge.